1 WHO/IARC.World cancer report 2014[M].Lyon:IARC Press,2014:738-750. 2 Zhang L,Wei WJ,Ji QH,et al.Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma:a study of 1066 patients[J].J Clin Endocrinol Metab,2012,97(4):1250-1257. 3 Sakorafas GH,Giotakis J,Stafyla V.Papillary thyroid microcarcinoma:a surgical perspective[J].Cancer Treat Rev,2005,31(6):423-438. 4 高慧霞.超声诊断甲状腺微小乳头状癌的价值与临床病理对照[J].中国继续医学教育,2015,7(20):69-70. 5 Moon WJ,Baek JH,Jung SL,et al.Ultrasonography and the ultrasound-based management of thyroid nodules:consensus statement and recommendations[J].Korean J Radiol,2011,12(1):1-14. 6 Md HB,Alexander EK,Bible KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133. 7 Ferraz C,Eszlinger M,Paschke R.Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules[J].J Clin Endocrinol Metab,2011,96(7):2016-2026. 8 Adeniran AJ,Theoharis C,Hui P,et al.Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation:a prospective study[J].Thyroid,2011,21(7):717-723. 9 Melo M,Da RA,Vinagre J,et al.TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas[J].J Clin Endocrinol Metab,2014,99(5):E754-765. 10 Xing M,Liu R,Liu X,et al.BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence[J].J Clin Oncol,2014,32(25):2718-2726. 11 Liu X,Qu S,Liu R,et al.TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer[J].J Clin Endocrinol Metab,2014,99(6):1130-1136. 12 中华医学会内分泌学分会,中华医学会外科学分会,中国抗癌协会头颈肿瘤专业委员会,中华医学会核医学分会.甲状腺结节和分化型甲状腺癌诊治指南[J].中国肿瘤临床,2012,39(17):1249-1272. 13 Li F,Chen G,Sheng C,et al.BRAF V600E mutation in papillary thyroid microcarcinoma:a meta-analysis[J].Endocr Relat Cancer,2015,22(2):159-168. 14 Zhou YL,Zhang W,Gao EL,et al.Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma[J].Asian Pac J Cancer Prev,2012,13(4):1267-1272. 15 Ito Y,Miyauchia A,Kihara M,et al.Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation[J].Thyroid,2014,24(1):27-34. 16 Zheng X,Wei S,Han Y,et al.Papillary microcarcinoma of the thyroid:clinical characteristics and BRAF(V600E)mutational status of 977 cases[J].Ann Surg Oncol,2013,20(7):2266-2273. 17 Valcavi R,Piana S,Bortolan GS,et al.Ultrasound-guided percutaneous laser ablation of papillary thyroid microcarcinoma:a feasibility study on three cases with pathological and immunohistochemical evaluation[J].Thyroid,2013,23(12):1578-1582. 18 刘晓岭,黄靖,孙德胜,等.超声引导下射频消融治疗甲状腺微小乳头状癌的临床体会[J].黑龙江医学,2015,39(1):69-70. 19 Creach KM,Siegel BA,Nussenbaum B,et al.Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma[J].ISRN Endocrinol,2012,2012:8163-8186. 20 Sabaretnam M,Ramakant,Abraham DT,et al.Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma[J].Clinical Endocrinology,2013,78(4):444-445. 21 Lang HH,Wong IOL,Kai PW,et al.Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy[J].Surgery,2012,151(6):844-850. |